Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.60 |
| ▸ | TTR known ✓ | P02766 | 2/20 | 0.41 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.37 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA4 | P22748 | 2/20 | 0.60 |
| ▸ | CA6 | P23280 | 2/20 | 0.60 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122413 | 0.98 | CA1 (0.62) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL30873490 | 0.98 | CA1 (0.62) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6914826 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6914824 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL28389071 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6915503 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6916922 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6914855 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6913327 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 | |
| SCHEMBL6913898 | 0.95 | CA1 (0.60) | CA1CA2CA4CA6PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831814-B | A kind of thieno [3,2-d] miazines HIV-1 reverse transcriptase inhibitor and its preparation method and application | 山东大学 | 2018-11-23 | — | — | CN | claimed |
| CN-106831814-A | A kind of thieno [3,2 d] RTIs of miazines HIV 1 and its preparation method and application | 山东大学 | 2017-06-13 | — | — | CN | claimed |
| CN-1211183-A | Methods for preparation of biphenyl isoxazole sulfonamides | BRISTOL MYERS SQUIBB CO (US) | 1999-03-17 | — | — | CN | claimed |
| EP-3653230-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220017459-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11174223-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3653230-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2569019-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109053762-A | PPAP hemiketal class compound, Its Preparation Method And Use | 贵州省中国科学院天然产物化学重点实验室 | 2018-12-21 | — | — | CN | disclosed |
| CN-105829305-B | NRF2 regulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-30 | — | — | CN | disclosed |
| US-7700800-B2 | Method for producing fluorine-containing alkyl (meth)acrylate | TOKUYAMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090023948-A1 | Method for Producing Fluorine-Containing Alkyl (Meth)Acrylate | TOKUYAMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| CN-1897944-A | Benzenesulfonamido-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity | AGOURON PHARMA (US) | 2007-01-17 | — | — | CN | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| CN-1211183-A | Methods for preparation of biphenyl isoxazole sulfonamides | BRISTOL MYERS SQUIBB CO (US) | 1999-03-17 | — | — | CN | disclosed |
| US-5021543-A | Process for the production of bifunctional OH-terminated polyphenylene oxides with dipolar aprotic solvent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
| US-4089861-A | NEUROLEPTIC AGENT | HOFFMANN-LA ROCHE, INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4060549-A | Process for preparing sulfonic acid fluorides | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | CA2 1389/4885TTR 2333/4885MAPK14 2861/4885 |
| US-20220017459-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CA2 32/4885TTR 119/4885MAPK14 4203/4885 |
| US-11174223-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | CA2 32/4885TTR 119/4885MAPK14 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.